Price (delayed)
$0.9601
Market cap
$14.04M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.62
Enterprise value
$9.3M
Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of ...
Highlights
IMNN's debt is down by 30% YoY and by 10% from the previous quarter
The company's EPS rose by 25% YoY and by 14% QoQ
The equity has dropped by 68% year-on-year and by 48% since the previous quarter
Imunon's quick ratio has decreased by 42% YoY and by 35% from the previous quarter
Key stats
What are the main financial stats of IMNN
MarketValuationsEarnings
Shares outstanding
14.62M
Market cap
$14.04M
Enterprise value
$9.3M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.28
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$19.13M
Net income
-$18.62M
EBIT
-$18.62M
EBITDA
-$17.9M
Free cash flow
-$18.88M
Per shareBalance sheetLiquidity
EPS
-$1.62
EPS diluted
-$1.62
Free cash flow per share
-$1.64
Book value per share
$0.29
Revenue per share
$0
TBVPS
$0.84
Total assets
$9.72M
Total liabilities
$5.47M
Debt
$1.14M
Equity
$4.24M
Working capital
$3.22M
Debt to equity
0.27
Current ratio
1.67
Quick ratio
1.23
Net debt/EBITDA
0.26
MarginsEfficiencyDividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-154.8%
Return on equity
-301.8%
Return on invested capital
-786.7%
Return on capital employed
-377.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IMNN stock price
How has the Imunon stock price performed over time
Intraday
-3.99%
1 week
-11.92%
1 month
13.62%
1 year
-30.93%
YTD
1.06%
QTD
-8.56%
Financial performance
How have Imunon's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$19.13M
Net income
-$18.62M
Gross margin
N/A
Net margin
N/A
IMNN financials
IMNN's operating income is up by 9% YoY and by 9% QoQ
The net income has grown by 4.6% YoY and by 4.3% from the previous quarter
Growth
What is Imunon's growth rate over time
IMNN growth chart
Valuation
What is Imunon stock price valuation
P/E
N/A
P/B
3.28
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Price to earnings (P/E)
The company's EPS rose by 25% YoY and by 14% QoQ
Price to book (P/B)
IMNN's price to book (P/B) is 134% higher than its 5-year quarterly average of 1.4 and 31% higher than its last 4 quarters average of 2.5
The equity has dropped by 68% year-on-year and by 48% since the previous quarter
Price to sales (P/S)
Efficiency
How efficient is Imunon business performance
Imunon's return on assets has shrunk by 133% YoY and by 20% QoQ
IMNN's ROIC has shrunk by 86% QoQ
The ROE has contracted by 31% from the previous quarter
Dividends
What is IMNN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IMNN.
Financial health
How did Imunon financials performed over time
Assets vs liabilities
The total assets is 78% more than the total liabilities
The total assets has plunged by 56% YoY and by 32% from the previous quarter
Imunon's quick ratio has decreased by 42% YoY and by 35% from the previous quarter
Debt vs equity
IMNN's debt is 73% less than its equity
IMNN's debt to equity has soared by 125% YoY and by 80% QoQ
The equity has dropped by 68% year-on-year and by 48% since the previous quarter
Balance sheet
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from 
and Sharadar.